Our data demonstrate that BCL2 and BCL(X)L inhibition profoundly impacts on mitochondrial ATP production, and that a combined treatment of BCL2 or BCL(X)L selective inhibitors and glycolysis inhibitors produced synthetic lethality in estrogen receptor positive (ER+) and TNBC breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.